REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN ARDS
ARDS 中巨噬细胞炎症表型的调节
基本信息
- 批准号:10094230
- 负责人:
- 金额:$ 56.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-01-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:ADP ribosylationAblationAcute Lung InjuryAddressAdoptive TransferAdult Respiratory Distress SyndromeAffectAffinityAlveolarAlveolar MacrophagesAntibioticsApoptosisAttenuatedBindingBleomycinBlood capillariesBone MarrowCalcineurinCaringCellsChimera organismClinicalCritical IllnessDataDevelopmentEndotheliumFamilyFunctional disorderGene ExpressionGenerationsGeneticHealthHumanHypoxemiaInflammationInflammatoryIntensive Care UnitsKnockout MiceLaboratoriesLifeLigandsLiquid substanceLungMeasuresMediatingMediator of activation proteinMethodsMolecularMolecular TargetMorbidity - disease rateMusOutcomeOxygenPathogenesisPatient-Focused OutcomesPeptidesPermeabilityPharmacological TreatmentPharmacologyPhenotypePneumoniaPrevention approachProductionProteolysisPublic HealthPulmonary EdemaPulmonary InflammationRecoveryRegulationResearchRoleTNF geneTNF-related apoptosis-inducing ligandTherapeutic AgentsVentilatorbasececal ligation punctureclinically relevantcytokinedesignexperimental studyhigh riskimprovedimproved outcomeinflammatory lung diseaseinhibitor/antagonistmacrophagemembermortalitymouse modelneutrophilnovelnovel strategiesnuclear factors of activated T-cellspatient populationpre-clinicalpreclinical efficacypreventpromoterpulmonary functionreconstitutionrecruitresponsetherapeutically effectivetranscription factortranscription factor NF-AT c3ventilation
项目摘要
PROJECT SUMMARY
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are neutrophilic inflammatory lung
diseases with unacceptably high rates of morbidity and mortality. Our supportive data indicate that genetic
ablation and pharmacologic inhibition of NFATc3 is beneficial in terms of tighter pulmonary barrier function,
decreased cytokine release and neutrophilic inflammation, improved arterial oxygenation, and better survival in
mouse models of ARDS/ALI. Based on these and other clinically relevant supportive data, we posit that
NFATc3 activation in macrophages induces inflammatory gene expression that mediates the initiation,
intensity and duration of ALI/ARDS. We propose three specific aims to address this hypothesis:
Specific Aim 1: To identify the mechanism(s) by which NFATc3 deletion protects against ALI/ARDS.
We will employ genetically defined mice that globally lack NFATc3 subjected to a well-defined murine model of
ALI/ARDS. We will also utilize established methods of NFATc3 KO/WT bone marrow chimera mice,
macrophage passive adoptive transfer of lung macrophages, and we will construct novel conditional
macrophage selective NFATc3-/- mice to identify the impact of macrophage NFATc3 deficiency on the
generation of pulmonary edema, arterial oxygen saturation, and mortality.
Specific Aim 2: To determine the mechanisms by which macrophage NFATc3 activation contributes to
the development of permeability pulmonary edema. In order to determine how macrophages contribute to
the pulmonary edema and severe hypoxemia in ALI/ARDS, we propose to examine the role of NFATc3
regulation of macrophage expression of TNF-related apoptosis-inducing ligand (TRAIL), which inhibits
alveolar fluid clearance (AFC), in addition to lung macrophage production of mediators that disrupt barrier
function of pulmonary microvascular endothelium.
Specific Aim 3: To determine the efficacy of a novel cell permeable peptide NFAT inhibitor in protecting
against ALI/ARDS-like pathophysiology in mouse models. Our group has developed a novel NFAT
inhibitor, CP9-ZIZIT, that has an impressively low Kd value of 2.6 nM, better cell permeability, higher binding
affinity, and improved stability against proteolysis than other available agents. We expect to show that
treatment with CP9-ZIZIT alone or in combination with a PARP1 inhibitor will attenuate pulmonary
inflammation and alveolar capillary barrier disruption.
We expect that this research will provide valuable preclinical data that blocking NFATc3 activation in
macrophages is an effective therapeutic agent for preventing ARDS in a high-risk patient population
and improving the clinical outcome of patients suffering from moderate and severe ARDS/ALI.
项目摘要
急性肺损伤(Acute lung injury,ALI)和急性呼吸窘迫综合征(acute respiratory Distress Syndrome,ARDS)是一种嗜酸性的炎症性肺损伤,
发病率和死亡率高得令人无法接受的疾病。我们的支持性数据表明,
NFATc 3的消融和药物抑制有利于增强肺屏障功能,
减少细胞因子释放和嗜酸性炎症,改善动脉氧合,
ARDS/ALI小鼠模型。基于这些和其他临床相关的支持性数据,我们认为,
巨噬细胞中的NFATc 3活化诱导介导启动的炎性基因表达,
ALI/ARDS的强度和持续时间。我们提出了三个具体目标来解决这个假设:
具体目的1:确定NFATc 3缺失保护免受ALI/ARDS的机制。
我们将采用遗传上确定的小鼠,其总体上缺乏NFATc 3,并进行明确的小鼠模型,
ALI/ARDS。我们还将利用已建立的NFATc 3 KO/WT骨髓嵌合体小鼠的方法,
巨噬细胞被动过继转移肺巨噬细胞,我们将构建新的条件
巨噬细胞选择性NFATc 3-/-小鼠,以确定巨噬细胞NFATc 3缺乏对
肺水肿的产生、动脉血氧饱和度和死亡率。
具体目标2:确定巨噬细胞NFATc 3激活有助于
发生渗透性肺水肿。为了确定巨噬细胞如何参与
在ALI/ARDS的肺水肿和严重低氧血症中,我们建议检查NFATc 3的作用
调节巨噬细胞表达肿瘤坏死因子相关凋亡诱导配体(TRAIL),其抑制
肺泡液清除率(AFC),以及肺巨噬细胞产生的介质破坏屏障
肺微血管内皮功能。
具体目的3:确定新型细胞渗透性肽NFAT抑制剂在保护细胞凋亡中的功效。
针对小鼠模型中的ALI/ARDS样病理生理学。我们的团队开发了一种新型的NFAT
抑制剂CP 9-ZIZIT,其具有令人印象深刻的低Kd值2.6 nM,更好的细胞渗透性,更高的结合
亲和性,以及比其他可用试剂改善的抗蛋白水解稳定性。我们希望能证明
单独使用CP 9-ZIZIT或与PARP 1抑制剂组合使用CP 9-ZIZIT的治疗将减弱肺动脉高压。
炎症和肺泡毛细血管屏障破坏。
我们希望这项研究将提供有价值的临床前数据,阻断NFATc 3激活,
巨噬细胞是预防高危患者群体中的ARDS的有效治疗剂
改善中重度ARDS/ALI患者的临床预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John W Christman其他文献
62 - NOSl-Derived Nitric Oxide Promotes NF-kB Transcriptional Activity Through Inhibition of Suppressor of Cytokine Signaling (SOCS-1)
- DOI:
10.1016/j.freeradbiomed.2015.10.101 - 发表时间:
2015-10-01 - 期刊:
- 影响因子:
- 作者:
Marcelo G Bonini;Sofia V Zaichik;Mao Mao;Peter C Hart;Saurabh Chatterjee;Asrar B. Malik;John W Christman;Michelle L. Block;Richard D Minshall;Benjamin N Gantner - 通讯作者:
Benjamin N Gantner
John W Christman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John W Christman', 18)}}的其他基金
REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN ARDS
ARDS 中巨噬细胞炎症表型的调节
- 批准号:
10650813 - 财政年份:2018
- 资助金额:
$ 56.37万 - 项目类别:
REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN ARDS
ARDS 中巨噬细胞炎症表型的调节
- 批准号:
10455872 - 财政年份:2018
- 资助金额:
$ 56.37万 - 项目类别:
NADPH OXIDASE REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN SEPSIS
NADPH 氧化酶对脓毒症巨噬细胞炎症表型的调节
- 批准号:
8078053 - 财政年份:2010
- 资助金额:
$ 56.37万 - 项目类别:
NADPH OXIDASE REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN SEPSIS
NADPH 氧化酶对脓毒症巨噬细胞炎症表型的调节
- 批准号:
8252156 - 财政年份:2010
- 资助金额:
$ 56.37万 - 项目类别:
NADPH OXIDASE REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN SEPSIS
NADPH 氧化酶对脓毒症巨噬细胞炎症表型的调节
- 批准号:
7944664 - 财政年份:2010
- 资助金额:
$ 56.37万 - 项目类别:
NADPH OXIDASE REGULATION OF THE MACROPHAGE INFLAMMATORY PHENOTYPE IN SEPSIS
NADPH 氧化酶对脓毒症巨噬细胞炎症表型的调节
- 批准号:
8776499 - 财政年份:2010
- 资助金额:
$ 56.37万 - 项目类别:
相似海外基金
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 56.37万 - 项目类别:
Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 56.37万 - 项目类别:
Standard Grant
Collaborative Research: CDS&E: An experimentally validated, interactive, data-enabled scientific computing platform for cardiac tissue ablation characterization and monitoring
合作研究:CDS
- 批准号:
2245152 - 财政年份:2023
- 资助金额:
$ 56.37万 - 项目类别:
Standard Grant